Search

Displaying results 5071 - 5080 of 7897 in total
  1. Drug

    Oxaprozin

    go.drugbank.com/drugs/DB00991
    Approved

    Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.

  2. Drug

    Zeranol

    go.drugbank.com/drugs/DB11478
    ExperimentalVet approved

    Zeranol is a non-steroidal estrogen agonist. It is a mycotoxin, derived from fungi in the Fusarium family, and may be found as a contaminant in fungus-infected crops. … It is 3-4x more potent as an estrogen agonist than the related compound zearalenone.

  3. Drug

    Troleandomycin

    go.drugbank.com/drugs/DB13179
    Approved

    A macrolide antibiotic that is similar to erythromycin.

  4. Drug

    Amsacrine

    go.drugbank.com/drugs/DB00276
    ApprovedInvestigationalWithdrawn

    Aminoacridine derivative that is a potent intercalating antineoplastic agent.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    GB-13

    go.drugbank.com/drugs/DB18387
    Experimental

    GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.

  6. Drug

    Pentetrazol

    go.drugbank.com/drugs/DB13415
    ApprovedWithdrawn

    Pentetrazol, also known as pentylenetetrazole, is a gamma-aminobutyric acid type A (GABA<sub>A</sub>) receptor antagonist that was approved by the FDA until 1982.[A254437]

  7. Drug

    Trilostane

    go.drugbank.com/drugs/DB01108
    ApprovedVet approvedWithdrawn

    Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.

  8. Drug

    AS1409

    go.drugbank.com/drugs/DB05182
    Investigational

    AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours. … It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma.

  9. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.

  10. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy. … with a possible increased risk of death outweighing the benefits.